HIV incidence and prevalence among adults aged 15-64 years in Rwanda: Results from the Rwanda Population-based HIV Impact Assessment (RPHIA) and District-level Modeling, 2019.
HIV
Incidence
Naomi model
Prevalence
Rwanda
population-based surveys
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
07
09
2021
revised:
10
01
2022
accepted:
13
01
2022
pubmed:
24
1
2022
medline:
3
3
2022
entrez:
23
1
2022
Statut:
ppublish
Résumé
The 2018-2019 Rwanda Population-based HIV Impact Assessment (RPHIA) was conducted to measure national HIV incidence and prevalence. District-level estimates were modeled to inform resources allocation. RPHIA was a nationally representative cross-sectional household survey. Consenting adults were interviewed and tested for HIV using the national diagnostic algorithm followed by laboratory-based confirmation of HIV status and testing for viral load (VL), limiting antigen (LAg) avidity, and presence of antiretrovirals. Incidence was calculated using normalized optical density ≤ 1·5, VL ≥ 1,000 copies/mL, and undetectable antiretrovirals. Survey and programmatic data were used to model district-level HIV incidence and prevalence. Of 31,028 eligible adults, 98·7% participated in RPHIA and 934 tested HIV positive. HIV prevalence among adults in Rwanda was 3·0% (95% CI:2·7-3·3). National HIV incidence was 0·08% (95% CI:0·02-0·14) and 0·11% (95% CI:0·00-0·26) in the City of Kigali (CoK). Based on district-level modeling, HIV incidence was greatest in the 3 CoK districts (0·11% to 0·15%) and varied across other districts (0·03% to 0·10%). HIV prevalence among adults in Rwanda is 3.0%; HIV incidence is low at 0.08%. District-level modeling has identified disproportionately affected urban hotspots: areas to focus resources.
Identifiants
pubmed: 35066161
pii: S1201-9712(22)00031-5
doi: 10.1016/j.ijid.2022.01.032
pmc: PMC9069967
mid: NIHMS1780735
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-254Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : CGH CDC HHS
ID : U2G GH001226
Pays : United States
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no conflict of interest to declare.
Références
Int J Equity Health. 2019 Oct 30;18(1):167
pubmed: 31666077
Lancet HIV. 2017 Oct;4(10):e457-e464
pubmed: 28801191
Nat Commun. 2019 Dec 2;10(1):5482
pubmed: 31792217
Int J STD AIDS. 2019 May;30(6):557-568
pubmed: 30727831
J Int AIDS Soc. 2021 Sep;24 Suppl 5:e25788
pubmed: 34546657
J Virus Erad. 2018 Nov 15;4(Suppl 2):1-4
pubmed: 30515307
Int J STD AIDS. 2015 Oct;26(11):810-4
pubmed: 25336306
Lancet HIV. 2018 May;5(5):e241-e249
pubmed: 29650451
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21635
pubmed: 28770591
Lancet. 2014 Jul 26;384(9940):371-5
pubmed: 24703831